ISSN: 1859 - 2872
Optimal bladder volume for hypofractionated radiotherapy planning in prostate cancer
Main Article Content
Keywords
Abstract
Objective: To determine the optimal bladder volume in hypofractionated radiotherapy planning for
prostate cancer, thereby improving simulation quality and reducing bladder complications.
Methods: A retrospective study was conducted on 27 patients with localized stage prostate cancer
treated with definitive hypofractionated radiotherapy. Bladder volume was assessed on simulation
CT images. ROC curve analysis was used to identify the optimal threshold of bladder volume for
radiotherapy planning, with the approved criteria of bladder volume receiving 60Gy (V60) less than
5%. Results: The mean age of patients was 72.0 ± 7.7 years. The proportions of patients in the
intermediate and high-risk groups were 22.2% and 77.8%, respectively. Pelvic lymph node
irradiation was performed in 37.0% of cases. The mean clinical target volume prescribed 60 Gy
(CTV60) was 39.4 ± 24.9 ml. The mean bladder volume was 198.6 ± 109.1 ml. Bladder volume was
a significant predictor of radiotherapy planning outcomes (AUC = 0.80, p = 0.009); with a threshold
of 240 ml, the sensitivity and specificity was 62.5% and 100%. Conclusion: Maintaining bladder
volume above 240 ml contributes to optimizing hypofractionated radiotherapy planning for prostate
cancer.
Article Details
References
<https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-
sheet.pdf?utm>, accessed: 28/8/2025
2. Siegel R.L., Miller K.D., Wagle N.S. et al. (2023). Cancer statistics, 2023. CA Cancer J
Clin, 73(1), 17–48.
3. Hamdy F.C., Donovan J.L., Lane J.A. et al. (2016). 10-Year Outcomes after Monitoring,
Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med, 375(15),
1415–1424.
4. Shaikh P.M., Iv J.A.A.V., Fareed M.M. et al. (2024). Hypofractionated vs.
Conventionally Fractionated Radiotherapy for Prostate Cancer: A Meta-Analysis of
Randomized Trials. Int J Radiat Oncol Biol Phys, 120(2), e582–e583.
5. Dearnaley D., Syndikus I., Mossop H. et al. (2016). Conventional versus
hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year
outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol, 17(8),
1047–1060.
6. Chen H.-H., Lin P.-T., Kuo L.-T. et al. (2021). Bladder volume reproducibility after
water consumption in patients with prostate cancer undergoing radiotherapy: A
systematic review and meta-analysis. Biomed J, 44(6 Suppl 2), S226–S234.
7. RTOG contouring guideline in prostate cancer RTOG contouring guideline in prostate
cancer. <https://econtour.org/training/intact_prostate_module.pdf>, accessed: 04/9/2025
8. Partin Tables. <https://www.hopkinsmedicine.org/brady-urology-institute/conditions-
and-treatments/prostate-cancer/risk-assessment-tools/partin-tables>, accessed:
04/09/2025.
9. Narita Y., Kato T., Ishikawa Y. et al. (2023). Optimal Bladder Volume for
Hypofractionated Proton Therapy in Each Localized Prostate Cancer Risk Group.
Cureus, 15(11), e48723.
10. Bodusz D., Brajczewska-Bello J., Rutkowski T. et al. (2024). The Role of Ultrasound-
Based Monitoring of Bladder Volume in Patients with Prostate Cancer during
CyberKnife Stereotactic Radiosurgery. Appl Sci, 14(19), 9091.
11. Rades D., Cremers F., Ziemann C. et al. (2024). Changes in Bladder Volume During
Radiotherapy for Prostate Cancer. Anticancer Res, 44(10), 4457–4463.
12. Huang S., Li T., Guo Y. et al. (2025). Impact of bladder volume and bladder shape on
radiotherapy consistency and treatment interruption in prostate cancer patients. J Appl
Clin Med Phys, 26(4), e70026.
Article Sidebar
